Lipid Biomarkers in Liquid Biopsies: Novel Opportunities for Cancer Diagnosis
Pharmaceutics · 28.01.2023 · 15 (2) · 437
DOI: 10.3390/pharmaceutics15020437 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 28.01.2023. Verfasst von Krizia Sagini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South-Eastern Norwegian Regional Health Authority, Norwegian Cancer Society, University of Perugia.
Abstract (Originalsprache)
Altered cellular metabolism is a well-established hallmark of cancer. Although most studies have focused on the metabolism of glucose and glutamine, the upregulation of lipid metabolism is also frequent in cells undergoing oncogenic transformation. In fact, cancer cells need to meet the enhanced demand of plasma membrane synthesis and energy production to support their proliferation. Moreover, lipids are precursors of signaling molecules, termed lipid mediators, which play a role in shaping the tumor microenvironment. Recent methodological advances in lipid analysis have prompted studies aimed at investigating the whole lipid content of a sample (lipidome) to unravel the complexity of lipid changes in cancer patient biofluids. This review focuses on the application of mass spectrometry-based lipidomics for the discovery of cancer biomarkers. Here, we have summarized the main lipid alteration in cancer patients’ biofluids and uncovered their potential use for the early detection of the disease and treatment selection. We also discuss the advantages of using biofluid-derived extracellular vesicles as a platform for lipid biomarker discovery. These vesicles have a molecular signature that is a fingerprint of their originating cells. Hence, the analysis of their molecular cargo has emerged as a promising strategy for the identification of sensitive and specific biomarkers compared to the analysis of the unprocessed biofluid.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379 Oslo, Norway.
- Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Montebello, 0379 Oslo, Norway.
- Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy.
- CEMIN (Center of Excellence for Innovative Nanostructured Material), University of Perugia, 06123 Perugia, Italy.
- Department for Mechanical, Electronics and Chemical Engineering, Oslo Metropolitan University, 0167 Oslo, Norway.
ORCID-Profile: Krizia Sagini, Lorena Urbanelli, Alicia Llorente
Förderung
- South-Eastern Norwegian Regional Health Authority
- Norwegian Cancer Society
- University of Perugia
Zitieren
APA
Sagini, K., Urbanelli, L., Buratta, S., Emiliani, C., & Llorente, A. (2023). Lipid Biomarkers in Liquid Biopsies: Novel Opportunities for Cancer Diagnosis. Pharmaceutics, 15(2), 437. https://doi.org/10.3390/pharmaceutics15020437
Vancouver
Sagini K, Urbanelli L, Buratta S, Emiliani C, Llorente A. Lipid Biomarkers in Liquid Biopsies: Novel Opportunities for Cancer Diagnosis. Pharmaceutics. 2023;15(2):437. doi:10.3390/pharmaceutics15020437
BibTeX
@article{Sagini2023,
author = {Sagini, Krizia and Urbanelli, Lorena and Buratta, Sandra and Emiliani, Carla and Llorente, Alicia},
title = {Lipid Biomarkers in Liquid Biopsies: Novel Opportunities for Cancer Diagnosis},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {2},
pages = {437},
doi = {10.3390/pharmaceutics15020437}
}
EUVIMED